| Identification | Back Directory | [Name]
naMitecan | [CAS]
372105-27-6 | [Synonyms]
ST-1968
naMitecan
1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(2-aminoethyl)oxime], [C(E),4S]- | [Molecular Formula]
C23H22N4O5 | [MDL Number]
MFCD19443712 | [MOL File]
372105-27-6.mol | [Molecular Weight]
434.44 |
| Chemical Properties | Back Directory | [Boiling point ]
835.2±75.0 °C(Predicted) | [density ]
1.51±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (575.45 mM) | [form ]
Solid | [pka]
11.20±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Namitecan is a potent topoisomerase I inhibitor, with antitumor property. | [in vivo]
Namitecan (10 mg/kg) in combination with cetuximab (1 mg/mouse) induces synergistic antitumor effects in SCC models as a function of EGFR gene copy number[1]. ST1968 (25 mg/kg) causes acceptable body weight loss and no toxic deaths. ST1968 produces a 100% complete response rate in the mice bearing the A431 tumor, and retains a relevant activity in the topotecan-resistant tumor[2]. | [IC 50]
Topoisomerase I | [storage]
Store at -20°C | [References]
[1] De Cesare M, et al. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number. Clin Cancer Res. 2014 Feb 15;20(4):995-1006. DOI:10.1158/1078-0432.CCR-13-1684
[2] Zuco V, et al. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol. 2010 Feb 15;79(4):535-41. DOI:10.1016/j.bcp.2009.09.012 |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|